Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis

Research output: Contribution to journalArticlepeer-review

84 Citations (Scopus)
232 Downloads (Pure)

Abstract

Constipation is a frequently overlooked side effect of clozapine treatment that can prove fatal. We conducted a systematic review and meta-analysis to estimate the prevalence and risk factors for clozapine-associated constipation. Two authors performed a systematic search of major electronic databases from January 1990 to March 2016 for articles reporting the prevalence of constipation in adults treated with clozapine. A random effects meta-analysis was conducted. A total of 32 studies were meta-analyzed, establishing a pooled prevalence of clozapine-associated constipation of 31.2% (95% CI: 25.6–37.4) (n = 2013). People taking clozapine were significantly more likely to be constipated versus other antipsychotics (OR 3.02 (CI: 1.91–4.77), p < 0.001, n = 11 studies). Meta-regression identified two significant study-level factors associated with constipation prevalence: significantly higher (p = 0.02) rates of constipation were observed for those treated in inpatient versus outpatient or mixed settings and for those studies in which constipation was a primary or secondary outcome measure (36.9%) compared to studies in which constipation was not a specified outcome measure (24.8%, p = 0.048). Clozapine-associated constipation is common and approximately three times more likely than with other antipsychotics. Screening and preventative strategies should be established and appropriate symptomatic treatment applied when required.
Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume17
Issue number6
DOIs
Publication statusPublished - 2 Jun 2016

Keywords

  • constipation; clozapine; treatment-resistant schizophrenia; adverse events; systematic review; meta-analysis

Cite this